Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056).

abstract：PURPOSE:This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients. METHODS:Five dose level combinations with irinotecan (from 180 to 240 mg/m(2), day 1, q21), capecitabine (1,...

journal_title：Cancer chemotherapy and pharmacology

authors： Bajetta E,Di Bartolomeo M,Buzzoni R,Ferrario E,Dotti KF,Mariani L,Bajetta R,Gevorgyan A,Venturino P,Galassi M

更新日期：2009-06-01 00:00:00

abstract：:This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamethasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alon...

journal_title：Cancer chemotherapy and pharmacology

authors： Frustaci S,Grattoni E,Tumolo S,Crivellari D,Figoli F,Galligioni E,Veronesi A,Tirelli U,Grigoletto E

更新日期：1986-01-01 00:00:00

abstract：:The novel anticancer compound GR63178A is being evaluated in the clinic, having demonstrated activity against a wide range of experimental tumour systems in animals without significant toxic side-effects being apparent. In this work, we have demonstrated significant antitumour action of this compound against one murin...

journal_title：Cancer chemotherapy and pharmacology

authors： French RC,Cummings J,MacLellan A,MacPherson JS,Ritchie AA,Smyth JF

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Afatinib is an irreversible ErbB family blocker currently under evaluation in late-stage clinical trials. This study primarily assessed the cardiac safety, pharmacokinetics and antitumor activity of afatinib in cancer patients. METHODS:In this multicenter, Phase II, open-label, single-arm trial, 60 patients wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Molife LR,Rudman SM,Alam S,Tan DS,Kristeleit H,Middleton G,Propper D,Bent L,Stopfer P,Uttenreuther-Fischer M,Wallenstein G,de Bono J,Spicer J

更新日期：2013-12-01 00:00:00

abstract：PURPOSE:4'-Thio-β-D-arabinofuranosylcytosine (4'-thio-ara-C), which has shown a broad spectrum of antitumor activity against human tumor systems in mice and is undergoing clinical trials, was evaluated for cross-resistance to seven clinical agents in order to identify potentially useful guides for patient selection for...

journal_title：Cancer chemotherapy and pharmacology

authors： Waud WR,Gilbert KS,Secrist JA 3rd

更新日期：2011-08-01 00:00:00

abstract：:Larotaxel (XRP9881, RPR109881), a novel semi-synthetic taxoid that shares a mode of action with the taxanes docetaxel and paclitaxel, was active in preclinical studies against a broad spectrum of tumour cells and tumour models refractory/resistant to taxanes, and have demonstrated clinical activity in taxane pre-treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamamoto N,Boku N,Minami H

更新日期：2009-12-01 00:00:00

abstract：:Activation of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells leads to T cell exhaustion and ultimately facilitates tumor progression. Recent success of using immune cell checkpoint inhibitors offers a great promise to treat various cancers, including bladder cancer. However, the exp...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang W,Shi L,Zhao Z,Du P,Ye X,Li D,Cai Z,Han J,Cai J

更新日期：2019-05-01 00:00:00

abstract：PURPOSE:Cytotoxic chemotherapy has been used to treat patients with metastatic colorectal cancer with limited success. Therefore novel chemotherapeutic approaches are needed. Based on encouraging preclinical data, there has been an interest in developing derivatives of butyrate as clinically applicable agents. The purp...

journal_title：Cancer chemotherapy and pharmacology

authors： Feinman R,Clarke KO,Harrison LE

更新日期：2002-01-01 00:00:00

abstract：:In order to determine if any inherent sensitivity differences may exist between VP16-213 and VM26 individual human tumors were grown in vitro and drug sensitivities were determined using the soft agar clonogenic assay method. Only nine of the 34 tumors tested so far showed a differing sensitivity to VP16-213 and VM26 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Issell BF,Tihon C,Curry ME

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:Preclinical research and prior clinical observations demonstrated reduced toxicity and suggested enhanced efficacy of cisplatin due to folic acid and vitamin B12 suppletion. In this randomized phase 2 trial, we evaluated the addition of folic acid and vitamin B12 to first-line palliative cisplatin and gemcitabi...

journal_title：Cancer chemotherapy and pharmacology

authors： van Zweeden AA,van Groeningen CJ,Honeywell RJ,Giovannetti E,Ruijter R,Smorenburg CH,Giaccone G,Verheul HMW,Peters GJ,van der Vliet HJ

更新日期：2018-07-01 00:00:00

abstract：:In five cancer patients we have determined the pharmacokinetics of 4'-deoxydoxorubicin (4'-DOX), its alcoholic metabolite 4'-deoxydoxorubicinol and the occurrence of circulating 7-deoxyaglycone metabolites. The 7-deoxyaglycone of the alcohol metabolite, the major aglycone of Adriamycin (ADR) present in man, was not de...

journal_title：Cancer chemotherapy and pharmacology

authors： Cummings J,Kerr DJ,Kaye SB

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:Capecitabine is a prodrug that undergoes metabolism in three steps to form an active 5-fluorouracil (5-FU). The first step is primarily catalyzed by liver carboxylesterases (CES) 1. Here, we examined the effects of CES1 variants on pharmacokinetics and toxicity of capecitabine. METHODS:We enrolled postoperativ...

journal_title：Cancer chemotherapy and pharmacology

authors： Matsumoto N,Kubota Y,Ishida H,Sekido M,Ohkuma R,Ishiguro T,Hirasawa Y,Ariizumi H,Tsunoda T,Ikusue T,Kobayashi K,Hisamatsu A,Toshima H,Shimada K,Fujita KI

更新日期：2020-06-01 00:00:00

abstract：PURPOSE:Nasopharyngeal carcinoma (NPC) is one of the most commonly diagnosed cancers worldwide with significantly high prevalence in Southern China. Chemoprevention of cancer with alkylating agent compounds could potentially reverse, suppress, or prevent cancer progression. Cisplatin (CIS) is an antineoplastic or cytot...

journal_title：Cancer chemotherapy and pharmacology

authors： Yin P,Song G,Jiang Z

更新日期：2018-05-01 00:00:00

abstract：:We investigated the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to two alkylating and crosslinking agents: chlorambucil and N,N',N"-triethylenethiophosphoramide (thiotepa). The cell lines studied in...

journal_title：Cancer chemotherapy and pharmacology

authors： Seidenfeld J,Komar KA,Naujokas MF,Block AL

更新日期：1986-01-01 00:00:00

abstract：:To predict the clinical effect on leukemic disease of a combination regimen developed to circumvent multidrug resistance (MDR), we tested various antitumor agents in the presence and absence of AHC-52, a sensitizing agent for multidrug-resistant cells, in the i.v.-i.v. model of murine leukemia. In this model system, s...

journal_title：Cancer chemotherapy and pharmacology

authors： Shinoda H,Ebisu H,Mitsuhashi J,Inaba M,Tsuruo T

更新日期：1992-01-01 00:00:00

abstract：:The ubiquitin-proteasome system (UPS) is an important system that regulates the balance of intracellular proteins, and it is involved in the regulation of multiple vital biological processes. The approval of bortezomib for relapsed and refractory multiple myeloma has proven that agents targeting the UPS have the poten...

journal_title：Cancer chemotherapy and pharmacology

authors： Ying J,Zhang M,Qiu X,Lu Y

更新日期：2018-05-01 00:00:00

abstract：:Interleukin 12 (IL-12) is a heterodimeric cytokine with a number of biological effects that are consistent with its potential role as an antitumor agent. The antimetastatic and antitumor activities of IL-12 have been demonstrated in a number of murine tumor models. Both the inhibition of established experimental pulmo...

journal_title：Cancer chemotherapy and pharmacology

authors： Brunda MJ,Luistro L,Rumennik L,Wright RB,Dvorozniak M,Aglione A,Wigginton JM,Wiltrout RH,Hendrzak JA,Palleroni AV

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:The platinum agent oxaliplatin could be useful in treatment of cancer in pregnant women, but it is fetotoxic in rats and its effect on the human fetus is unknown. METHODS:Oxaliplatin was administered to a 25-year-old pregnant woman with metastatic rectal cancer from 20 to 30 weeks gestational age as part of th...

journal_title：Cancer chemotherapy and pharmacology

authors： Gensheimer M,Jones CA,Graves CR,Merchant NB,Lockhart AC

更新日期：2009-01-01 00:00:00

abstract：PURPOSE:Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens containing busulfan because of non-disease-related morbidity and mortality. We hypothesized that busulfan clearance (BuCL) in older patients (>60 years) would be reduce...

journal_title：Cancer chemotherapy and pharmacology

authors： Beumer JH,Owzar K,Lewis LD,Jiang C,Holleran JL,Christner SM,Blum W,Devine S,Kolitz JE,Linker C,Vij R,Alyea EP,Larson RA,Ratain MJ,Egorin MJ

更新日期：2014-11-01 00:00:00

abstract：PURPOSE:The relationships between pharmacokinetic parameters of unchanged cisplatin (CDDP) and several markers for nephrotoxicity after CDDP infusion (80 mg/m2) over 2 and 4 h were quantitated in patients with various cancers (lung, stomach and colon cancers and mediastinal tumor). METHODS:Plasma and urinary levels of...

journal_title：Cancer chemotherapy and pharmacology

authors： Nagai N,Kinoshita M,Ogata H,Tsujino D,Wada Y,Someya K,Ohno T,Masuhara K,Tanaka Y,Kato K,Nagai H,Yokoyama A,Kurita Y

更新日期：1996-01-01 00:00:00

abstract：:MKT-077 (1-ethyl-2-[[3-ethyl-5-(3-methylbenzothiazolin-2-yliden)]-4- oxothiazolidin-2-ylidenemethyl] pyridinium chloride), a novel rhodacyanine dye in phase I/II clinical trials, may provide a new approach to cancer therapy based on the accumulation in the mitochondria of the cells of certain carcinomas, for example, ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tatsuta N,Suzuki N,Mochizuki T,Koya K,Kawakami M,Shishido T,Motoji N,Kuroiwa H,Shigematsu A,Chen LB

更新日期：1999-01-01 00:00:00

abstract：:A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy. Kinetic analyses were done to evaluate the tumor-cell-recruiting potential of the alkylating agent. Our study shows that ifosfamide can enhance tumor proliferative activity in pretreated ovarian cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Rosso R,Alama A,Repetto L,Conte PF

更新日期：1990-01-01 00:00:00

abstract：:Irinotecan-induced mucositis is a major oncological problem. Goblet cells secrete mucus, protecting the intestinal mucosa, with secretion altered during mucositis. The enteric nervous system is involved in regulating gut motility and secretion. The aim of this study was to determine whether enteric neural cells and go...

journal_title：Cancer chemotherapy and pharmacology

authors： Thorpe D,Sultani M,Stringer A

更新日期：2019-05-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer death in the world. Recently, targeted therapy and anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) immunotherapy have made great progress in treatment of lung cancer. However, responses to these therapies are variable, influenced b...

journal_title：Cancer chemotherapy and pharmacology

authors： Huang C,Liu S,Tong X,Fan H

更新日期：2018-08-01 00:00:00

abstract：:Cultures of human colon carcinoma, HCT-8, were treated with millimolar concentrations of thymidine by different schedules designed to cytokinetically and biochemically modulate methotrexate (MTX) and 5-fluorouracil (FUra) toxicity. Thymidine (dThd)-synchronized HCT-8 cells monitored by flow cytofluorometry showed incr...

journal_title：Cancer chemotherapy and pharmacology

authors： Benz C,Choti M,Newcomer L,Cadman E

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:Although cisplatin is an important agent in non-small-cell lung cancer (NSCLC), de novo resistance is common and acquired resistance emerges rapidly during therapy. Proposed mediators of platinum resistance include the protein kinase C (PKC) signal transduction pathway and associated c-FOS overexpression. While...

journal_title：Cancer chemotherapy and pharmacology

authors： Lara PN Jr,Gandara DR,Longmate J,Gumerlock PH,Lau DH,Edelman MJ,Gandour-Edwards R,Mack PC,Israel V,Raschko J,Frankel P,Perez EA,Lenz HJ,Doroshow JH

更新日期：2001-07-01 00:00:00

abstract：:UCN-01 (7-hydroxystaurosporine; NSC 638850) is a protein kinase antagonist selected for clinical trial based in part on evidence of efficacy in a preclinical renal carcinoma xenograft model. Schedule studies and in vitro studies suggested that a 72-h continuous infusion would be appropriate. In rats and dogs, maximum ...

journal_title：Cancer chemotherapy and pharmacology

authors： Sausville EA,Lush RD,Headlee D,Smith AC,Figg WD,Arbuck SG,Senderowicz AM,Fuse E,Tanii H,Kuwabara T,Kobayashi S

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:The established treatment for small-cell lung cancer has been a cisplatin-etoposide combination, as the most effective chemotherapy regimen. Paclitaxel has also been used in combination with cisplatin and etoposide but this has been unacceptable due to the toxicity. This toxicity could be attributed to the thre...

journal_title：Cancer chemotherapy and pharmacology

authors： Stathopoulos GP,Trafalis D,Dimitroulis J,Kosmas Ch,Stathopoulos J,Tsavdaridis D

更新日期：2013-02-01 00:00:00

abstract：PURPOSE:This study evaluated mechanistic differences of pralatrexate, methotrexate, and pemetrexed. METHODS:Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled pralatrexate, methot...

journal_title：Cancer chemotherapy and pharmacology

authors： Izbicka E,Diaz A,Streeper R,Wick M,Campos D,Steffen R,Saunders M

更新日期：2009-10-01 00:00:00

abstract：PURPOSE:Veliparib is an oral inhibitor of poly(ADP-ribose) polymerase enzyme. Combination of veliparib and temozolomide was well-tolerated and demonstrated clinical activity in older patients with relapsed or refractory acute myeloid leukemia (AML) or AML arising from pre-existing myeloid malignancies. We aimed to perf...

journal_title：Cancer chemotherapy and pharmacology

authors： Singh R,Mehrotra S,Gopalakrishnan M,Gojo I,Karp JE,Greer JM,Chen A,Piekarz R,Kiesel BF,Gobburu J,Rudek MA,Beumer JH,ETCTN-6745 study team.

更新日期：2019-02-01 00:00:00